AHAlexander Huppertz

Alexander Huppertz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alexander Huppertz has a total of 75 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Novel Dynamic Hepatic Magnetic Resonance Imaging Strategy Using Advanced Parallel Acquisition, Rhythmic Breath-Hold Technique, and Gadoxetate Disodium Enhancement

    by Ute Lina Fahlenkamp, Moritz Wagner, Dominik Nickel, Ulrich Adam, Karsten Krueger, Matthias Taupitz, Carsten Schwenke, Alexander Huppertz

    Objective The aim of the study was to evaluate image quality of a dynamic hepatic magnetic resonance (MR) imaging strategy based on advanced parallel acquisition combined with rhythmic breath-hold and gadoxetate disodium enhancement. Materials and Methods Twenty-seven patients (21 male/6 female; mean age, 57.3 years) were enrolled in this institutional review board–approved study and underwent MR imaging at 3 T. The sequence (T1 3-dimensional gradient-recalled echo; acceleration factor, 4; reconstruction mode; controlled aliasing in parallel imaging resulting in higher acceleration factors; acquisition time, 10.4 seconds) was repeated at 8 fixed time points within the 3 minutes after contrast agent injection. Image quality was evaluated on a 5-point scale (1, excellent; 5, nondiagnostic). Dynamic sequences were classified according to perfusion phases and contrast characteristics. Artifacts and position of the liver in the z axis were recorded and analyzed. Results Overall image quality was found to be 1.44 (95% confidence interval, 1.18–1.71). Contrast was scored as excellent in 25 of 27 patients for central vessels and 22 of 27 patients for peripheral vessels. Adequate-quality arterial-phase images were obtained in all 27 patients. Double arterial and single arterial phases were acquired in 13 of 27 and 14 of 27 patients (n = 6 arterial dominant, n = 8 early arterial phases), respectively. In 1 (3.7%) of 27 patients, severe respiratory artifacts were seen during an early arterial phase. Artifacts were observed in 21 of 27 patients and rated as mild in 19 of these. Compromised quality was related to receiver coils (17 of 29), parallel imaging (6 of 29), breathing (3 of 29), and other causes (3 of 29). The position of the liver throughout the dynamic phases was highly constant, with a greatest mean shift of +2.9 mm throughout the first dynamic acquisition. Conclusions Advanced parallel acquisition with rhythmic breath-hold and gadoxetate injection allows arterial phase imaging without breathing artifacts; a decelerated yet normal breathing pattern results in very robust breath-hold depth.


  • Ultra-low-dose dual-source CT coronary angiography with high pitch: diagnostic yield of a volumetric planning scan and effects on dose reduction and imaging strategy

    by M H Maurer, B Hamm, A Huppertz, A Lembcke

    To evaluate the role of an ultra-low-dose dual-source CT coronary angiography (CTCA) scan with high pitch for delimiting the range of the subsequent standard CTCA scan. 30 patients with an indication for CTCA were prospectively examined using a two-scan dual-source CTCA protocol (2.0 × 64.0 × 0.6 mm; pitch, 3.4; rotation time of 280 ms; 100 kV): Scan 1 was acquired with one-fifth of the tube current suggested by the automatic exposure control software [CareDose 4D™ (Siemens Healthcare, Erlangen, Germany) using 100 kV and 370 mAs as a reference] with the scan length from the tracheal bifurcation to the diaphragmatic border. Scan 2 was acquired with standard tube current extending with reduced scan length based on Scan 1. Nine central coronary artery segments were analysed qualitatively on both scans. Scan 2 (105.1 ± 10.1 mm) was significantly shorter than Scan 1 (127.0 ± 8.7 mm). Image quality scores were significantly better for Scan 2. However, in 5 of 6 (83%) patients with stenotic coronary artery disease, a stenosis was already detected in Scan 1 and in 13 of 24 (54%) patients with non-stenotic coronary arteries, a stenosis was already excluded by Scan 1. Using Scan 2 as reference, the positive- and negative-predictive value of Scan 1 was 83% (5 of 6 patients) and 100% (13 of 13 patients), respectively. An ultra-low-dose CTCA planning scan enables a reliable scan length reduction of the following standard CTCA scan and allows for correct diagnosis in a substantial proportion of patients. Further dose reductions are possible owing to a change in the individual patient's imaging strategy as a prior ultra-low-dose CTCA scan may already rule out the presence of a stenosis or may lead to a direct transferal to an invasive catheter procedure.


  • Intraindividual comparison of T1 relaxation times after gadobutrol and Gd-DTPA administration for cardiac late enhancement imaging

    by Patrick Doeblin, Rene Schilling, Moritz Wagner, Reny Luhur, Alexander Huppertz, Bernd Hamm, Matthias Taupitz, Tahir Durmus


  • Computed tomography for preoperative planning in total hip arthroplasty: what radiologists need to know

    by Alexander Huppertz, Sebastian Radmer, Moritz Wagner, Torsten Roessler, Bernd Hamm, Martin Sparmann

    The number of total hip arthroplasties is continuously rising. Although less invasive surgical techniques, sophisticated component design, and intraoperative navigation techniques have been introduced, the rate of peri- and postoperative complications, including dislocations, fractures, nerve palsies, and infections, is still a major clinical problem. Better patient outcome, faster recovery and rehabilitation, and shorter operation times therefore remain to be accomplished. A promising strategy is to use minimally invasive techniques in conjunction with modular implants, aimed at independently reconstructing femoral offset and leg length on the basis of highly accurate preoperative planning. Plain radiographs have clear limitations for the correct estimation of hip joint geometry and bone quality. Three-dimensional assessment based on computed tomography (CT) allows optimizing the choice and positions of implants and anticipating difficulties to be encountered during surgery. Postoperative CT is used to monitor operative translation and plays a role in arthroplastic quality management. Radiologists should be familiar with the needs of orthopedic surgeons in terms of CT acquisition, post-processing, and data transfer. The CT protocol should be optimized to enhance image quality and reduce radiation exposure. When dedicated orthopedic CT protocols and state-of-the-art scanner hardware are used, radiation exposure can be decreased to a level just marginally higher than that of conventional preoperative radiography. Surgeons and radiologists should use similar terminology to avoid misunderstanding and inaccuracies in the transfer of preoperative planning.


  • Systemic staging for urate crystal deposits with dual-energy CT and ultrasound in patients with suspected gout

    by Alexander Huppertz, Kay-Geert A. Hermann, Torsten Diekhoff, Moritz Wagner, Bernd Hamm, Wolfgang A. Schmidt

    Objective of the study is to compare the diagnostic accuracy for detecting monosodium urate crystal deposits between dual-energy CT (DECT) and ultrasound (US). Sixty consecutive patients (49 men, mean age 62 years) with clinically suspected gout were included in this case–control study. DECT and US of feet, knees, hands and elbows were performed in all patients. Polarisation microscopy of synovial fluid or a score incorporating serum uric acid level, first MTP joint involvement, gender, previous patient-reported arthritis attack, cardiovascular diseases, joint redness and onset within 1 day was used as standard of reference. Standard of reference classified 39 patients as gout positive. Sixteen patients had gout and a concomitant rheumatic disease. Sensitivities for diagnosis of gout disease were 84.6 % (33/39) for DECT and 100 % (39/39) for US. Specificities were 85.7 % (18/21) for DECT and 76.2 % (16/21) for US. Positive and negative predictive values were 91.7 % (33/36) and 75.0 % (18/24) for DECT, 88.6 % (39/44) and 100 % (16/16) for US, respectively. Urate crystals were detected most frequently in MTP1 joints (DECT 20/78, US 58/78), any other toe joints (DECT 25/78, US 62/78) and knees (DECT 41/78, US 31/78). The volumetry of DECT computed a mean urate crystal deposit load of 2.1 cm3 (SD 9.6 cm3). A mean effective dose of ≤0.5 mSv was estimated. DECT is more specific for the diagnosis of gout than US. However, it fails to detect small urate crystal deposits. It might be particularly useful for patients with ambivalent findings, concomitant rheumatic diseases and with non-conclusive joint aspiration.


  • Pharmacokinetic Approach for Dynamic Breast MRI to Indicate Signal Intensity Time Curves of Benign and Malignant Lesions by Using the Tumor Flow Residence Time

    by Diane Miriam Renz, Felix Diekmann, Florian Frowin Schmitzberger, Hubertus Pietsch, Eva Maria Fallenberg, Tahir Durmus, Alexander Huppertz, Joachim Böttcher, Ulrich Bick, Bernd Hamm, et al.

    Objective The objective of this study was to evaluate a novel pharmacokinetic approach integrating a tumor model in a whole-body pharmacokinetic model to simulate contrast media-induced signal intensity time curves of breast tumors on dynamic contrast-enhanced magnetic resonance mammography. Materials and Methods A recently developed, whole-body pharmacokinetic model, which describes the distribution and excretion of renally discharged contrast media, has been expanded by integrating a tumor model. The parameters of the general approach including exchange between plasma and interstitium were set as fixed values; only 2 tumor-specific parameters, blood volume fraction Vblood and blood flow kt, were varied. These parameters were adjusted with regard to signal intensity time course data of histologically verified benign and malignant mass-like breast lesions on clinical magnetic resonance imaging examinations (1.5 T) using 2 different contrast media (gadopentetate dimeglumine and gadoterate meglumine) and 2 application doses (0.1 and 0.2 mmol kg−1 body weight). Thus, measured signal intensity time curves were compared with simulated gadolinium (Gd) concentration time curves calculated by the pharmacokinetic model. Results Benign lesions showed continuous signal increase; malignant tumors presented fast initial signal increase followed by washout effect. According to the pharmacokinetic approach, the variation of the Vblood/kt ratio, which defined the tumor flow residence time τr, led to Gd concentration time curves congruent with the shapes of the measured signal intensity time curves. Low values of τr were characteristic for malignant tumors, and high values were typical for benign lesions; τr of 200 seconds best separated malignant from benign tumors. Thus, the dynamic magnetic resonance imaging data can be well approximated by the pharmacokinetic model considering 2 contrast media and application doses. The calculated Gd concentration time curves of 0.1 mmol kg−1 body weight gadopentetate dimeglumine and gadoterate meglumine overlapped for benign lesions; the curve of gadoterate meglumine was by a factor of 0.8 below the curve of gadopentetate dimeglumine for malignant tumors. Doubling the application dose of gadopentetate dimeglumine from 0.1 to 0.2 mmol kg−1 led to an increase in the Gd concentration time curves for benign lesions but not for malignant tumors. High Gd concentrations with values greater than 1 mmol L−1 were calculated in the vessels of the malignant tumors, outside the determined range of the linear relationship between Gd concentration and signal intensity due to saturation effects. Conclusions On the basis of this pharmacokinetic model, the contrast media-induced time curves on dynamic contrast-enhanced magnetic resonance mammography can be classified by a single kinetic parameter, the tumor flow residence time τr, into benign (τr >200 seconds) and malignant (τr <200 seconds) curve shapes. Possible clinical application of this model is to create pharmacokinetic maps, displaying tumor flow residence times, for computer-assisted diagnosis, which may be integrated into clinical routine for the diagnosis of breast lesions.


  • Open Access

    Cost-effectiveness of cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary artery disease in Germany

    by Julia Boldt, Alexander W Leber, Klaus Bonaventura, Christian Sohns, Martin Stula, Alexander Huppertz, Wilhelm Haverkamp, Marc Dorenkamp


  • Open Access

    Single beat 3D echocardiography for the assessment of right ventricular dimension and function after endurance exercise: Intraindividual comparison with magnetic resonance imaging

    by Sebastian Schattke, Moritz Wagner, Robert Hättasch, Sabrina Schroeckh, Tahir Durmus, Ingolf Schimke, Wasiem Sanad, Sebastian Spethmann, Jürgen Scharhag, Alexander Huppertz, et al.

    Background: Our study compares new single beat 3D echocardiography (sb3DE) to cardiovascular magnetic resonance imaging (CMR) for the measurement of right ventricular (RV) dimension and function immediately after a 30 km run. This is to validate sb3DE against the "gold standard" CMR and to bring new insights into acute changes of RV dimension and function after endurance exercise. Methods: 21 non-elite male marathon runners were examined by sb3DE (Siemens ACUSON SC2000, matrix transducer 4Z1c, volume rates 10-29/s), CMR (Siemens Magnetom Avanto, 1,5 Tesla) and blood tests before and immediately after each athlete ran 30 km. The runners were not allowed to rehydrate after the race. The order of sb3DE and CMR examination was randomized. Results: Sb3DE for the acquisition of RV dimension and function was feasible in all subjects. The decrease in mean body weight and the significant increase in hematocrit indicated dehydration. RV dimensions measured by CMR were consistently larger than measured by sb3DE. Neither sb3DE nor CMR showed a significant difference in the RV ejection fraction before and after exercise. CMR demonstrated a significant decrease in RV dimensions. Measured by sb3DE, this decrease of RV volumes was not significant. Conclusion: First, both methods agree well in the acquisition of systolic RV function. The dimensions of the RV measured by CMR are larger than measured by sb3DE. After exercise, the RV volumes decrease significantly when measured by CMR compared to baseline. Second, endurance exercise seems not to induce acute RV dysfunction in athletes without rehydration.


  • Computed tomography for preoperative planning in minimal-invasive total hip arthroplasty: Radiation exposure and cost analysis

    by Alexander Huppertz, Sebastian Radmer, Patrick Asbach, Ralf Juran, Carsten Schwenke, Gerd Diederichs, Bernd Hamm, Martin Sparmann


  • Evaluation of possible drug–drug interaction between gadoxetic acid and erythromycin as an inhibitor of organic anion transporting peptides (OATP)

    by Alexander Huppertz, Josy Breuer, Lueder M. Fels, Marcus Schultze‐Mosgau, Gabriele Sutter, Stefan Klein, Bernd Frericks, Bernd Hamm, Moritz Wagner

    Purpose: To evaluate if erythromycin compromises liver‐specific enhancement of gadoxetic acid; both compounds competing in organic anion transporting peptides (OATP) ‐mediated hepatocytic uptake.Materials and Methods: The study was approved by institutional review board. Twelve healthy subjects (nine men, three woman; mean age, 38.7 years) were examined twice by MR imaging with prior administration of NaCl solution (placebo) or 1000 mg of erythromycin following a randomized sequence. Gadoxetic acid (0.025 mmol/kg body weight) was administered 15 min after the end of infusions. Pre‐ and 20 min postcontrast two‐dimensional gradient‐recalled‐echo sequences were acquired. Relative enhancements of liver parenchyma and ratio of means were calculated from signal intensity measurements. Plasma levels of gadoxetic acid and erythromycin were determined and given in geometric means and coefficients of variation (CV).Results: Concentration of erythromycin directly after end of infusion was 13.9 mg/L (CV 14.9%). Gadolinium plasma concentrations 5 min after gadoxetic acid administration were 138.7 μmol/L (CV 20.4%) after erythromycin infusion and 129.6 μmol/L (CV 22.8%) after placebo. Mean relative enhancements of liver parenchyma were 88.1 (SD 24.9%) after erythromycin infusion and 92.6 (SD 17.9%) after placebo. Ratio of relative enhancements was 0.951 (95% confidence interval, 0.833; 1.061; statistically not significant).Conclusion: Coadministration of erythromycin has no effect on gadoxetic acid enhanced liver MR imaging. J. Magn. Reson. Imaging 2011;33:409–416.